Shionogi & Co., Ltd.

Shionogi & Co., Ltd., an Osaka, Japan-based pharmaceutical company established in 1878, focuses on the discovery, development, production, and commercialization of medicines, diagnostic tools, and medical devices primarily within Japan. The company, known as Shionogi Shoten Co., Ltd. until its rebranding in 1943, maintains a comprehensive portfolio. Its marketed products include Fetroja, an agent for multidrug-resistant gram-negative bacterial infections; Xofluza, an antiviral treatment for influenza; and Tivicay, utilized in HIV therapy. Shionogi's extensive pipeline features investigational therapies such as Symproic for opioid-induced constipation; S-120083 for inflammatory pain and S-010887 for neuropathic pain; S-117957 for insomnia; sivopixant, addressing neuropathic pain, sleep apnea syndrome, and persistent chronic cough; S-637880 for neuropathic low back pain; Zuranolone for depression; SDT-001 for attention-deficit/hyperactivity disorder; BPN14770 for Fragile X syndrome and Alzheimer's disease; and S-237648 and S-309309 for obesity. Further development initiatives encompass ADR-001 for decompensated liver cirrhosis; S-723595 for NASH; various oncology candidates including S-588410 for esophageal and bladder cancer, S-488210 for head and neck squamous cell carcinoma, S-588210 for solid tumors, S-222611 for malignant tumors, and S-531011 for solid tumors; S-770108 for idiopathic pulmonary fibrosis; SR-0379 for cutaneous ulcers; S-005151 for stroke and epidermolysis bullosa; S-0373 for spinocerebellar ataxia; and multiple compounds targeting COVID-19, such as S-600918, S-217622, and S-555739 for mitigating disease progression. Additionally, the firm offers antibody test kits for COVID-19. Shionogi fosters strategic alliances, including collaborations with Nagasaki University, the National Institute of Infectious Diseases, and The Kitasato University, aimed at advancing antimalarial drug research.

CEO: Isao Teshirogi - https://www.shionogi.com